Ameritas Investment Partners’s Protalix BioTherapeutics PLX Stock Holding History

Ameritas Investment Partners’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.4K	Hold	7,119	–	–	﹤0.01%	2714
2025 Q4	$12.8K	Hold	7,119	–	–	﹤0.01%	2830
2025 Q3	$15.8K	Hold	7,119	–	–	﹤0.01%	2778
2025 Q2	$10.5K	Buy	+7,119	New	+$14.6K	﹤0.01%	2964
2024 Q2	–	Sell	-4,638	Closed	-$5.84K	–	3209
2024 Q1	$5.84K	Hold	4,638	–	–	﹤0.01%	2931
2023 Q4	$8.26K	Hold	4,638	–	–	﹤0.01%	2892
2023 Q3	$7.7K	Hold	4,638	–	–	﹤0.01%	2903
2023 Q2	$9.28K	Buy	+4,638	New	+$11.1K	﹤0.01%	2929

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Ameritas Investment Partners's PLX Position: Q1 2026 in Review

Ameritas Investment Partners held its Protalix BioTherapeutics (PLX) position steady in Q1 2026 at 7,119 shares worth $15.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2714.

Ameritas Investment Partners first reported a position in PLX in Q2 2023 and has held it in 8 quarters since. The position peaked at $15.8K in Q3 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Ameritas Investment Partners held 7,119 shares of Protalix BioTherapeutics worth $15.4K as of Q1 2026.
Ameritas Investment Partners left its Protalix BioTherapeutics share count unchanged in Q1 2026.
Protalix BioTherapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2714 holding.
Ameritas Investment Partners first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 8 quarters since.
Ameritas Investment Partners's Protalix BioTherapeutics position peaked at $15.8K in Q3 2025.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.